drugset / Trial / NCT02152371
A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes
RandomizedParallel-groupDouble-blindTreatment
Summary
The main purpose of this study is to evaluate the use of the study drug known as dulaglutide in participants with type II diabetes who are taking once-daily insulin glargine. The study will last about 31 weeks for each participant.
Timeline
- Start
- 2014-05
- Primary completion
- 2015-10
- Completion
- 2015-10
Outcome
Met primary endpoint
registry Dulaglutide + Insulin Glargine vs Placebo + Insulin Glargine; p <.001; LS Means Diff -0.77 (95% CI -0.97 to -0.56) NCT02152371 ↗
Publications
- Pantalone KM, Patel H, Yu M, Fernandez Lando L. Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration. Diabetes Obes Metab. 2018 Jun;20(6):1461-1469. doi: 10.1111/dom.13252. Epub 2018 Mar 23.
- Yu M, Brunt KV, Milicevic Z, Varnado O, Boye KS. Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9). Clin Ther. 2017 Nov;39(11):2284-2295. doi: 10.1016/j.clinthera.2017.10.002. Epub 2017 Oct 27.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dulaglutide | Peptide | 1.5 mg | Subcutaneous |
| Background | Metformin | Small molecule | — | Oral |
| Background | insulin glargine | Protein / enzyme biologic | — | Subcutaneous |